{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:06:39Z","timestamp":1792951599339,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation under","doi-asserted-by":"crossref","award":["2023MD734135"],"award-info":[{"award-number":["2023MD734135"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing","doi-asserted-by":"crossref","award":["CSTB2023NSCQ-BHX0019"],"award-info":[{"award-number":["CSTB2023NSCQ-BHX0019"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04137-6","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T06:26:42Z","timestamp":1754461602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination of low-intensity pulsed ultrasound irradiating immune organs with immune checkpoint blockade augments systemic anti-tumor immunity on low tumor burden 4T-1 breast cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Jixi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqing","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"1","key":"4137_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348","journal-title":"CA Cancer J Clin"},{"key":"4137_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I (2022) Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66:15\u201323","journal-title":"Breast"},{"issue":"7","key":"4137_CR3","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.21037\/tcr-22-2799","volume":"12","author":"X Qian","year":"2023","unstructured":"Qian X, Zou X, Xiu M, Liu Y, Chen X, Xiao M, Zhang P (2023) Epidemiology and clinicopathologic features of breast cancer in China and the United States. Transl Cancer Res 12(7):1826\u20131835","journal-title":"Transl Cancer Res"},{"key":"4137_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP (2023) Advances in systemic therapies for triple negative breast cancer. BMJ 381:e071674","journal-title":"BMJ"},{"issue":"1","key":"4137_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, Wu K (2023) Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol 16(1):100","journal-title":"J Hematol Oncol"},{"key":"4137_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS (2022) Pathogenesis of triple-negative breast cancer. Annu Rev Pathol 17:181\u2013204","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"4137_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103008","volume":"9","author":"SWM Lammers","year":"2024","unstructured":"Lammers SWM, Meegdes M, Vriens IJH, Voogd AC, de Munck L, van Nijnatten TJA, Keymeulen KBMI, Tjan-Heijnen VCG, Geurts SME (2024) Treatment and survival of patients diagnosed with high-risk HR+\/HER2-breast cancer in the Netherlands: a population-based retrospective cohort study. ESMO Open 9(5):103008","journal-title":"ESMO Open"},{"issue":"1","key":"4137_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9\u201320","journal-title":"N Engl J Med"},{"issue":"4","key":"4137_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3857\/roj.2017.00416","volume":"35","author":"KJ Ahn","year":"2017","unstructured":"Ahn KJ, Park J, Choi Y (2017) Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery. Radiat Oncol J 35(4):332\u2013339","journal-title":"Radiat Oncol J"},{"key":"4137_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102434","volume":"109","author":"F De Rose","year":"2022","unstructured":"De Rose F, Meduri B, De Santis MC, Ferro A, Marino L, Colciago RR, Gregucci F, Vanoni V, Apolone G, Di Cosimo S, Delaloge S, Cortes J, Curigliano G (2022) Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treat Rev 109:102434","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"4137_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.25122\/jml-2021-0108","volume":"15","author":"A Baranova","year":"2022","unstructured":"Baranova A, Krasnoselskyi M, Starikov V, Kartashov S, Zhulkevych I, Vlasenko V, Oleshko K, Bilodid O, Sadchikova M, Vinnyk Y (2022) Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. J Med Life 15(2):153\u2013161","journal-title":"J Med Life"},{"issue":"21","key":"4137_CR12","doi-asserted-by":"publisher","first-page":"12015","DOI":"10.3390\/ijms222112015","volume":"22","author":"C Cilibrasi","year":"2021","unstructured":"Cilibrasi C, Papanastasopoulos P, Samuels M, Giamas G (2021) Reconstituting immune surveillance in breast cancer: molecular pathophysiology and current immunotherapy strategies. Int J Mol Sci 22(21):12015","journal-title":"Int J Mol Sci"},{"issue":"25","key":"4137_CR13","doi-asserted-by":"publisher","first-page":"7749","DOI":"10.7150\/thno.37131","volume":"9","author":"ND Sheybani","year":"2019","unstructured":"Sheybani ND, Price RJ (2019) Perspectives on recent progress in focused ultrasound immunotherapy. Theranostics 9(25):7749\u20137758","journal-title":"Theranostics"},{"key":"4137_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3389\/fimmu.2019.00911","volume":"10","author":"N J\u00f8rgensen","year":"2019","unstructured":"J\u00f8rgensen N, Persson G, Hviid T (2019) The tolerogenic function of regulatory T cells in pregnancy and cancer. Front Immunol 10:911","journal-title":"Front Immunol"},{"issue":"12","key":"4137_CR15","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1016\/j.immuni.2023.11.002","volume":"56","author":"T Taifour","year":"2023","unstructured":"Taifour T, Attalla SS, Zuo D, Gu Y, Sanguin-Gendreau V, Proud H, Solymoss E, Bui T, Kuasne H, Papavasiliou V, Lee CG, Kamle S, Siegel PM, Elias JA, Park M, Muller WJ (2023) The tumor-derived cytokine Chi3l1 inducesneutrophil extracellular traps that promote T cell exclusion in triple-negative breastcancer. Immunity 56(12):2755\u20132772","journal-title":"Immunity"},{"issue":"21","key":"4137_CR16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137750","volume":"131","author":"B Ma","year":"2021","unstructured":"Ma B, Akosman B, Kamle S, Lee CM, He CH, Koo JS, Lee CG, Elias JA (2021) CHl3L1 regulates PD-L1 and anti-CHl3L1-PD-1antibody elicits synergistic antitumor responses. J Clin Invest 131(21):e137750","journal-title":"J Clin Invest"},{"issue":"11","key":"4137_CR17","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.3390\/cancers13112559","volume":"13","author":"S Gandhi","year":"2021","unstructured":"Gandhi S, Oshi M, Murthy V, Repasky EA, Takabe K (2021) Enhanced thermogenesis in triple-negative breast cancer is associated with pro-tumor immune microenvironment. Cancers 13(11):2559","journal-title":"Cancers"},{"issue":"4","key":"4137_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, Goncalves A, Mu\u00f1oz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J (2021) Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol 22(4):499\u2013511","journal-title":"Lancet Oncol"},{"issue":"2","key":"4137_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.21037\/tau.2016.02.04","volume":"5","author":"Z Xin","year":"2016","unstructured":"Xin Z, Lin G, Lei H, Lue TF, Guo Y (2016) Clinical applications of low-intensity pulsed ultrasound and its potential role in urology. Transl Androl Urol 5(2):255\u2013266","journal-title":"Transl Androl Urol"},{"key":"4137_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13018-015-0221-9","volume":"10","author":"U Farkash","year":"2016","unstructured":"Farkash U, Bain O, Gam A, Nyska M, Sagiv P (2016) Low-intensity pulsed ultrasound for treating delayed union scaphoid fractures: case series. J Orthop Surg Res 10:72","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"4137_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/02656736.2022.2025924","volume":"39","author":"Y Qin","year":"2022","unstructured":"Qin Y, Zhao X, Dong X, Liu J, Wang L, Wu X, Peng B, Li C (2022) Low-intensity ultrasound promotes uterine involution after cesarean section: the first multicenter, randomized, controlled clinical trial. Int J Hyperthermia 39(1):181\u2013189","journal-title":"Int J Hyperthermia"},{"issue":"12","key":"4137_CR22","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1631\/jzus.B1200129","volume":"13","author":"ZM Ying","year":"2012","unstructured":"Ying ZM, Lin T, Yan SG (2012) Low-intensity pulsed ultrasound therapy: a potential strategy to stimulate tendon-bone junction healing. J Zhejiang Univ Sci B 13(12):955\u2013963","journal-title":"J Zhejiang Univ Sci B"},{"issue":"5","key":"4137_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","volume":"24","author":"AM Sonabend","year":"2023","unstructured":"Sonabend AM, Gould A, Amidei C, Ward R, Schmidt KA, Zhang DY, Gomez C, Bebawy JF, Liu BP, Bouchoux G, Desseaux C, Helenowski IB, Lukas RV, Dixit K, Kumthekar P, Arrieta VA, Lesniak MS, Carpentier A, Zhang H, Muzzio M, Canney M, Stupp R (2023) Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol 24(5):509\u2013522","journal-title":"Lancet Oncol"},{"issue":"9","key":"4137_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ijbiomac.2015.06.052","volume":"80","author":"K Zhong","year":"2015","unstructured":"Zhong K, Tong L, Liu L, Zhou X, Liu X, Zhang Q, Zhou S (2015) Immunoregulatory and antitumor activity of schizophyllan under ultrasonic treatment. Int J Biol Macromol 80(9):302\u2013308","journal-title":"Int J Biol Macromol"},{"issue":"9","key":"4137_CR25","doi-asserted-by":"publisher","first-page":"BSR20201350","DOI":"10.1042\/BSR20201350","volume":"40","author":"W Wang","year":"2020","unstructured":"Wang W, Luo D, Chen J, Chen J, Xia Y, Chen W, Wang Y (2020) Amelioration of cyclophosphamide-induced myelosuppression during treatment to rats with breast cancer through low-intensity pulsed ultrasound. Biosci Rep 40(9):BSR20201350","journal-title":"Biosci Rep"},{"issue":"3","key":"4137_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00262-023-03613-1","volume":"73","author":"Y Xia","year":"2024","unstructured":"Xia Y, Yang M, Xiao X, Tang W, Deng J, Wu L, Xu H, Tang Y, Chen W, Wang Y (2024) Low-intensity pulsed ultrasound activated the anti-tumor immunity by irradiating the spleen of mice in 4T\u20131 breast cancer. Cancer Immunol Immunother 73(3):50","journal-title":"Cancer Immunol Immunother"},{"issue":"33","key":"4137_CR27","doi-asserted-by":"publisher","first-page":"eaau6085","DOI":"10.1126\/sciimmunol.aau6085","volume":"4","author":"SM Lewis","year":"2019","unstructured":"Lewis SM, Williams A, Eisenbarth SC (2019) Structure and function of the immune system in the spleen. Sci Immunol 4(33):eaau6085","journal-title":"Sci Immunol"},{"issue":"1","key":"4137_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cmi.2011.47","volume":"9","author":"E Zhao","year":"2012","unstructured":"Zhao E, Xu H, Wang L, Kryczek I, Wu K, Hu Y, Wang G, Zou W (2012) Bone marrow and the control of immunity. Cell Mol Immunol 9(1):11\u201319","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"4137_CR29","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3892\/ol.2021.12886","volume":"22","author":"W Jiang","year":"2021","unstructured":"Jiang W, Li Y, Zhang S, Kong G, Li Z (2021) Association between cellular immune response and spleen weight in mice with hepatocellular carcinoma. Oncol Lett 22(2):625","journal-title":"Oncol Lett"},{"issue":"44","key":"4137_CR30","doi-asserted-by":"publisher","first-page":"30701","DOI":"10.1021\/acsnano.4c09902","volume":"18","author":"Z Luo","year":"2024","unstructured":"Luo Z, Lin Y, Meng Y, Li M, Ren H, Shi H, Cheng Q, Wei T (2024) Spleen-targeted mRNA vaccine doped with manganese adjuvant for robust anticancer immunity in vivo. ACS Nano 18(44):30701\u201330715","journal-title":"ACS Nano"},{"issue":"1","key":"4137_CR31","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41467-019-08721-0","volume":"10","author":"DP Zachs","year":"2019","unstructured":"Zachs DP, Offutt SJ, Graham RS, Kim Y, Mueller J, Auger JL, Schuldt NJ, Kaiser CRW, Heiller AP, Dutta R, Guo H, Alford JK, Binstadt BA, Lim HH (2019) Noninvasive ultrasound stimulation of the spleen to treat inflammatory arthritis. Nat Commun 10(1):951","journal-title":"Nat Commun"},{"issue":"2","key":"4137_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/CCO.0000000000000602","volume":"32","author":"J Al-Sabah","year":"2020","unstructured":"Al-Sabah J, Baccin C, Haas S (2020) Single-cell and spatial transcriptomics approaches of the bone marrow microenvironment. Curr Opin Oncol 32(2):146\u2013153","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"4137_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12307-008-0010-7","volume":"1","author":"CF Chantrain","year":"2008","unstructured":"Chantrain CF, Feron O, Marbaix E, DeClerck YA (2008) Bone marrow microenvironment and tumor progression. Cancer Microenviron 1(1):23\u201335","journal-title":"Cancer Microenviron"},{"issue":"1","key":"4137_CR34","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1038\/s41598-022-10637-7","volume":"12","author":"S Katiraei","year":"2022","unstructured":"Katiraei S, van Diepen JA, Tavares LP, Hoving LR, Pronk A, Verschueren I, Rensen PCN, Zwaginga JJ, Kostidis S, Giera M, Teixera M, van Dijk KW, Netea MG, Berb\u00e9e JFP, van Harmelen V (2022) Bone marrow transplantation induces changes in the gut microbiota that chronically increase the cytokine response pattern of splenocytes. Sci Rep 12(1):6883","journal-title":"Sci Rep"},{"issue":"8","key":"4137_CR35","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s42255-023-00853-4","volume":"5","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xu M, Sun J, Li X, Shi H, Wang X, Liu B, Zhang T, Jiang X, Lin L, Li Q, Huang Y, Liang Y, Hu M, Zheng F, Zhang F, Sun J, Shi Y, Wang Y (2023) Glycolytic neutrophils accrued in the spleen compromise anti-tumour T cell immunity in breast cancer. Nat Metab 5(8):1408\u20131422","journal-title":"Nat Metab"},{"issue":"1\u20132","key":"4137_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","volume":"28","author":"RE Tay","year":"2021","unstructured":"Tay RE, Richardson EK, Toh HC (2021) Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther 28(1\u20132):5\u201317","journal-title":"Cancer Gene Ther"},{"issue":"12","key":"4137_CR37","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41577-023-00884-8","volume":"23","author":"JM Schenkel","year":"2023","unstructured":"Schenkel JM, Pauken KE (2023) Localization, tissue biology and T cell state - implications for cancer immunotherapy. Nat Rev Immunol 23(12):807\u2013823","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"4137_CR38","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K (2019) CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234(6):8509\u20138521","journal-title":"J Cell Physiol"},{"issue":"7596","key":"4137_CR39","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature17412","volume":"531","author":"W Yang","year":"2016","unstructured":"Yang W, Bai YB, Xiong Y, Zhang J, Chen S, Zheng X, Meng X, Li L, Wang J, Xu C, Yan C, Wang L, Chang CC, Chang TY, Zhang T, Zhou P, Song BL, Liu W, Sun SC, Liu X, Li BL, Xu C (2016) Potentiating the antitumour response of CD8+T cells by modulating cholesterol metabolism. Nature 531(7596):651\u2013655","journal-title":"Nature"},{"issue":"3","key":"4137_CR40","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA (2023) The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell 41(3):374\u2013403","journal-title":"Cancer Cell"},{"issue":"4","key":"4137_CR41","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jordao MJC, Joyce JA (2021) Therapeutic targeting of the tumor microenvironment. Cancer Discov 11(4):933\u2013959","journal-title":"Cancer Discov"},{"issue":"1","key":"4137_CR42","first-page":"3","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI (2017) Myeloid-derived suppressor cells. Cancer. Immunol Res 5(1):3\u20138","journal-title":"Immunol Res"},{"issue":"13","key":"4137_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108571","volume":"33","author":"T Kwak","year":"2020","unstructured":"Kwak T, Wang F, Deng H, Condamine T, Kumar V, Perego M, Kossenkov A, Montaner LJ, Xu X, Xu W, Zheng C, Schuchter LM, Amaravadi RK, Mitchell TC, Karakousis GC, Mulligan C, Nam B, Masters G, Hockstein N, Bennett J, Nefedova Y, Gabrilovich DI (2020) Distinct populations of immune-suppressive macrophages differentiate from monocytic myeloid-derived suppressor cells in cancer. Cell Rep 33(13):108571","journal-title":"Cell Rep"},{"key":"4137_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.smim.2017.12.004","volume":"35","author":"J Zhou","year":"2018","unstructured":"Zhou J, Nefedova Y, Lei A, Gabrilovich D (2018) Neutrophils and PMN-MDSC: their biological role and interaction with stromal cells. Semin Immunol 35:19\u201328","journal-title":"Semin Immunol"},{"issue":"5","key":"4137_CR45","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/10815589241239577","volume":"72","author":"X Chen","year":"2024","unstructured":"Chen X, Lin X, Xia X, Xiang X (2024) YAP1-induced RBM24 promotes the tumorigenesis of triple-negative breast cancer through the \u03b2-catenin pathway. J Investig Med 72(5):403\u2013413","journal-title":"J Investig Med"},{"issue":"7","key":"4137_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.616547","volume":"3","author":"X Zhou","year":"2021","unstructured":"Zhou X, Zhang FY, Liu Y, Wei DX (2021) A Risk prediction model for breast cancer based on immune genes related to early growth response proteins family. Front Mol Biosci 3(7):616547","journal-title":"Front Mol Biosci"},{"issue":"9","key":"4137_CR47","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/biomedicines8090334","volume":"8","author":"CK Looi","year":"2020","unstructured":"Looi CK, Hii LW, Ngai SC, Leong CO, Mai CW (2020) The role of ras-associated protein 1 (Rap1) in cancer: bad actor or good player? Biomedicines 8(9):334","journal-title":"Biomedicines"},{"issue":"6","key":"4137_CR48","first-page":"408","volume":"24","author":"H Yan","year":"2015","unstructured":"Yan H, Kamiya T, Suabjakyong P, Tsuji NM (2015) Targeting C-type lectin receptors for cancer immunity. Front Immunol 24(6):408","journal-title":"Front Immunol"},{"issue":"12","key":"4137_CR49","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.3390\/cancers11122002","volume":"11","author":"KL Owen","year":"2019","unstructured":"Owen KL, Brockwell NK, Parker BS (2019) JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers 11(12):2002","journal-title":"Cancers"},{"issue":"2","key":"4137_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000150","volume":"2","author":"A Kitano","year":"2017","unstructured":"Kitano A, Ono M, Yoshida M, Noguchi E, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fujiwara Y, Tsuda H, Tamura K (2017) Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1and PD-L1 in early breast cancer. ESMO Open 2(2):e000150","journal-title":"ESMO Open"},{"issue":"7","key":"4137_CR51","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S (2019) Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 37(7):559\u2013569","journal-title":"J Clin Oncol"},{"issue":"5","key":"4137_CR52","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang AC, Zappasodi R (2022) A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol 23(5):660\u2013670","journal-title":"Nat Immunol"},{"issue":"1","key":"4137_CR53","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41590-024-02027-0","volume":"26","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Langenbach M, Sagar S, Fetsch V, Stritzker J, Severa E, Meng K, Winkler F, Rana N, Zoldan K, Godbole I, Solis S, Weber JS, Rafei-Shamsabadi D, Lehr S, Diehl R, Venhoff AC, Voll RE, Buettner N, Neumann-Haefelin C, Boettler T, Hofmann M, Boerries M, Meiss F, Zeiser R, Thimme R, Herati RS, Bengsch B (2025) Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells. Nat Immunol 26(1):92\u2013104","journal-title":"Nat Immunol"},{"key":"4137_CR54","doi-asserted-by":"publisher","first-page":"7458","DOI":"10.1038\/ncomms8458","volume":"6","author":"ME Mikucki","year":"2015","unstructured":"Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS (2015) Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun 6:7458","journal-title":"Nat Commun"},{"issue":"5","key":"4137_CR55","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger S, Dai D, Horton B, Gajewski TF (2017) Tumor-residing batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31(5):711\u2013723","journal-title":"Cancer Cell"},{"issue":"11","key":"4137_CR56","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.it.2023.09.003","volume":"44","author":"V Niederlova","year":"2023","unstructured":"Niederlova V, Tsyklauri O, Kovar M, Stepanek O (2023) IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy. Trends Immunol 44(11):890\u2013901","journal-title":"Trends Immunol"},{"issue":"670","key":"4137_CR57","doi-asserted-by":"publisher","first-page":"eabo5409","DOI":"10.1126\/scitranslmed.abo5409","volume":"14","author":"ME Raeber","year":"2022","unstructured":"Raeber ME, Sahin D, Boyman O (2022) Interleukin-2-based therapies in cancer. Sci Transl Med 14(670):eabo5409","journal-title":"Sci Transl Med"},{"issue":"1","key":"4137_CR58","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e6","volume":"20","author":"DS Kuen","year":"2020","unstructured":"Kuen DS, Kim BS, Chung Y (2020) IL-17-producing cells in tumor immunity: friends or foes? Immune Netw 20(1):e6","journal-title":"Immune Netw"},{"issue":"4","key":"4137_CR59","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","volume":"50","author":"MJ McGeachy","year":"2019","unstructured":"McGeachy MJ, Cua DJ, Gaffen SL (2019) The IL-17 family of cytokines in health and disease. Immunity 50(4):892\u2013906","journal-title":"Immunity"},{"issue":"13","key":"4137_CR60","doi-asserted-by":"publisher","first-page":"20741","DOI":"10.18632\/oncotarget.15119","volume":"8","author":"X Wu","year":"2017","unstructured":"Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X, Li J, Li C, Yan M, Zhu Z, Liu B, Su L (2017) IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2\/STAT3 signaling pathway. Oncotarget 8(13):20741\u201320750","journal-title":"Oncotarget"},{"issue":"1","key":"4137_CR61","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41419-021-04461-6","volume":"13","author":"B Zhong","year":"2021","unstructured":"Zhong B, Cheng B, Huang X, Xiao Q, Niu Z, Chen YF, Yu Q, Wang W, Wu XJ (2021) Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6\/STAT3 signaling. Cell Death Dis 13(1):16","journal-title":"Cell Death Dis"},{"issue":"2","key":"4137_CR62","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41388-023-02885-2","volume":"43","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Qi F, Zhou C, Ji J, Jiang J, Wang C, Zhao Q, Jin Y, Wu J, Cai Q, Tian H, Zhang J (2024) VPS35 promotes gastric cancer progression through integrin\/FAK\/SRC signalling-mediated IL-6\/STAT3 pathway activation in a YAP-dependent manner. Oncogene 43(2):106\u2013122","journal-title":"Oncogene"},{"issue":"3","key":"4137_CR63","doi-asserted-by":"publisher","first-page":"e010612","DOI":"10.1136\/jitc-2024-010612","volume":"13","author":"H Jeong","year":"2025","unstructured":"Jeong H, Koh J, Kim S, Yim J, Song SG, Kim H, Li Y, Lee SH, Chung YK, Kim H, Lee CH, Kim HY, Keam B, Lee SH, Chung DH, Jeon YK (2025) Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer. J Immunother Cancer 13(3):e010612","journal-title":"J Immunother Cancer"},{"issue":"10","key":"4137_CR64","doi-asserted-by":"publisher","first-page":"8880","DOI":"10.18632\/aging.205847","volume":"16","author":"J Fan","year":"2024","unstructured":"Fan J, Wang L, Zhang C, Wu X, Han L, Zhang X, Gao S, Xue J, Zhang Q (2024) PDIA3 driven STAT3\/PD-1 signaling promotes M2 TAM polarization and aggravates colorectal cancer progression. Aging 16(10):8880\u20138897","journal-title":"Aging"},{"issue":"16","key":"4137_CR65","doi-asserted-by":"publisher","first-page":"eadt4258","DOI":"10.1126\/sciadv.adt4258","volume":"11","author":"HC Hsieh","year":"2025","unstructured":"Hsieh HC, Young MJ, Chen KY, Su WC, Lin CC, Yen YT, Hung JJ, Wang YC (2025) Deubiquitinase USP24 activated by IL-6\/STAT3 enhances PD-1 protein stability and suppresses T cell antitumor response. Sci Adv 11(16):eadt4258","journal-title":"Sci Adv"},{"key":"4137_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155976","volume":"158","author":"W Li","year":"2022","unstructured":"Li W, Wu Z, Meng W, Zhang C, Cheng M, Chen Y, Zou Y, Li K, Lin S, Xiong W, Wang Y, Lin Y, Ma W, Zhou W (2022) Blockade of IL-6 inhibits tumor immune evasion and improves anti-PD-1 immunotherapy. Cytokine 158:155976","journal-title":"Cytokine"},{"issue":"11","key":"4137_CR67","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1134\/S0006297916110055","volume":"81","author":"KN Atretkhany","year":"2016","unstructured":"Atretkhany KN, Drutskaya MS (2016) Myeloid-derived suppressor cells and proinflammatory cytokines as targets for cancer therapy. Biochemistry (Mosc) 81(11):1274\u20131283","journal-title":"Biochemistry (Mosc)"},{"key":"4137_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104254","volume":"359","author":"R Weber","year":"2021","unstructured":"Weber R, Groth C, Lasser S, Arkhypov I, Petrova V, Altevogt P, Utikal J, Umansky V (2021) IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol 359:104254","journal-title":"Cell Immunol"},{"key":"4137_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.794251","volume":"13","author":"JHA Clubb","year":"2022","unstructured":"Clubb JHA, Kudling TV, Heini\u00f6 C, Basnet S, Pakola S, Cervera Carrasc\u00f3n V, Santos JM, Quixabeira DCA, Havunen R, Sorsa S, Zheng V, Salo T, B\u00e4ck L, Aro K, Tulokas S, Loimu V, Hemminki A (2022) Adenovirus encoding tumor necrosis factor alpha and inter leukin 2 induces a tertiary lymphoid structure signature in immune checkpoint inhibitor refractory head and neck cancer. Front Immunol 13:794251","journal-title":"Front Immunol"},{"issue":"5","key":"4137_CR70","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1412902","volume":"7","author":"SM Cervera-CV","year":"2018","unstructured":"Cervera-CV SM, Santos JM, Havunen R, T\u00e4htinen S, Karell P, Sorsa S, Kanerva A, Hemminki A (2018) TNF\u03b1 and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology 7(5):e1412902","journal-title":"Oncoimmunology"},{"issue":"1","key":"4137_CR71","doi-asserted-by":"publisher","first-page":"2241710","DOI":"10.1080\/2162402X.2023.2241710","volume":"12","author":"TV Kudling","year":"2023","unstructured":"Kudling TV, Clubb JHA, Pakola S, Quixabeira DCA, L\u00e4hdeniemi IAK, Heini\u00f6 C, Arias V, Havunen R, Cervera-Carrascon V, Santos JM, Sutinen E, R\u00e4s\u00e4nen J, Borenius K, M\u00e4yr\u00e4np\u00e4\u00e4 MI, Aaltonen E, Sorsa S, Hemminki O, Kanerva A, Verschuren EW, Ilonen I, Hemminki A (2023) Effective intravenous delivery of adenovirus armed with TNF\u03b1 and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer. Oncoimmunology 12(1):2241710","journal-title":"Oncoimmunology"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04137-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04137-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04137-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:03:07Z","timestamp":1758733387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04137-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":71,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["4137"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04137-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were approved by Institutional Animal Care and Use of Chongqing Medical University and conducted in strict accordance with the Regulations on the Management of Experimental Animals. The animal ethics approval number is: IACUC-CQMU-2024-0983.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"281"}}